

Recommendations from York and Scarborough Medicines Commissioning Committee September 2015

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Alprostadil 3 mg/g cream (Vitaros®)	Erectile dysfunction	Approved	As per CCG referral support service guidance.	Approved for use after full trial of PDE-5 inhibitors failed or are contraindicated in line with CCG RSS guidance	Green	Less costly than other alprostadil products for erectile dysfunction.
Vitamin B compound strong tablets	Re-feeding syndrome	Approved	NICE CG 32 and local gastroenterology clinician opinions.	Uses supported by NICE CG and local clinicians indicate some patients require use beyond the initial 10 day period.	Amber – specialist initiation	Limited – savings expected from decommissioning for alcohol detoxification.
Naloxegol (Moventig®)	Opioid induced constipation	Approved	Approved in accordance with NICE TA 345 .	For those who have not responded to at least 2 full dose laxatives and dietary advice.	Green	Limited use in palliative care.
Vedolizumab (Entyvio®)	Crohn's Disease	Approved	Approved in accordance with NICE TA 352 .	Where anti TNF therapy has failed/contraindicated.	Red	Local figures to be confirmed.
Edoxaban (Lixiana®)	Treatment / prevention of recurrent DVT and PE	Approved	Approved in accordance with NICE TA 354 .	Is an option for treating DVT/PE alongside the other commissioned NOAC's and warfarin.	Green	Unlikely to have any significant cost impact as would

						displace other commissioned options.
Fumaric acid esters (Fumaderm®) unlicensed	Plaque psoriasis	Approved	Confirmation of current position.	Stated as plaque psoriasis unresponsive to conventional therapy (topical agents, phototherapy) or where contraindicated.	Red	No cost to CCG.
Toujeo® 300 units/ml (insulin glargine) pre-filled pen	Diabetes mellitus	Approved	Provides high dose insulin at less cost than insulin degludec.	For patients on insulin glargine (Lantus®) who require: <ul style="list-style-type: none"> • High dose (60+ units) per dose • Large volume of insulin + local site reactions • Twice daily insulin <p>NOTE: Toujeo 300mg/mL is not bioequivalent to insulin glargine 100mg/mL.</p>	Green	No significant cost pressure expected. Costs less than Tresiba® (insulin glargine).
Tresiba® ▼ (Insulin degludec)	Diabetes mellitus	Approved	Toujeo® is the 1 st choice high strength insulin. Insulin degludec would be an option after Toujeo®.	For use in patients for whom insulin U500 would otherwise be prescribed and for patients with significant nocturnal hypoglycaemia.	Amber – specialist initiation	Toujeo® 300 units/ml costs less than Tresiba® (insulin glargine).
Prucalopride 1mg/2mg (Resolor®)	Chronic constipation in men	Approved	Clinical evidence does not support use in men.	Not routinely commissioned	Black	No cost impact.

Other items to approve:

- CCG RSS guidance on erectile dysfunction
- Fosfomycin leaflet – update on licensed indication